Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.54 |
| ▸ | GMNN | O75496 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | CETP | P11597 | 3/20 | 0.54 |
| ▸ | UBE2N | P61088 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549711 | 0.91 | LMNA (0.50) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL29092693 | 0.84 | LMNA (0.46) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL11590828 | 0.84 | LMNA (0.46) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL465390 | 0.84 | LMNA (0.59) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL9550799 | 0.83 | LMNA (0.47) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL11897247 | 0.81 | OPRM1 (0.43) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL14702968 | 0.81 | ALDH1A1 (0.48) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL3837397 | 0.80 | ALDH1A1 (0.46) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL28919262 | 0.79 | LMNA (0.39) | CYP2D6MAPTLMNASPHK1GMNN | |
| SCHEMBL5371282 | 0.79 | ALDH1A1 (0.44) | CYP2D6MAPTLMNASPHK1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7842718-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050196813-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-09-08 | — | — | US | disclosed |
| US-6878742-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH | 2003-12-11 | — | — | US | disclosed |
| EP-1341779-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | disclosed |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE | 2002-12-05 | — | — | US | disclosed |
| WO-2002057252-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | CYP2D6 783/4885MAPT 19/4885LMNA 1273/4885 |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, PSEN1 | CYP2D6 1351/4885MAPT 26/4885LMNA 1423/4885 |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | CYP2D6 1351/4885MAPT 26/4885LMNA 1423/4885 |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | CYP2D6 783/4885MAPT 19/4885LMNA 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.